Home / Deep Research / Berardinelli-Seip Congenital Lipodystrophy

Berardinelli-Seip Congenital Lipodystrophy

Berardinelli-Seip Congenital Lipodystrophy Deep Research Fallback

⚠️ Fallback MONDO:0018883

Berardinelli-Seip Congenital Lipodystrophy Deep Research Fallback

Date: 2026-05-04T12:09Z

Provider Attempts

  • timeout 120 just research-disorder falcon Berardinelli_Seip_Congenital_Lipodystrophy
  • Result: timed out after the bounded 120-second run and was terminated by signal 15.
  • Completed artifact: none.
  • timeout 120 just research-disorder openai Berardinelli_Seip_Congenital_Lipodystrophy
  • Result: timed out after the bounded 120-second run and was terminated by signal 15.
  • Completed artifact: none.

No provider-generated deep-research narrative was available within the bounded runtime. Curation therefore proceeded from regenerated structured Orphanet evidence and fetched PubMed caches, without hand-editing any references_cache/*.md files.

Evidence Scope Used For Curation

Structured Source

  • ORPHA:528 congenital generalized lipodystrophy structured record
  • Exact MONDO cross-reference: MONDO:0018883
  • Inheritance: autosomal recessive
  • Natural history: neonatal, infantile, and childhood onset categories
  • Worldwide point-prevalence band: 1-9 / 1 000 000
  • Frequent or very frequent HPO phenotypes integrated in the YAML: insulin resistance, hepatomegaly, skeletal muscle hypertrophy, adipose tissue loss, lipodystrophy, diabetes mellitus, hypertrichosis, intellectual disability, and hypertriglyceridemia
  • Additional ORPHA phenotypes integrated where mechanistically relevant: hepatic steatosis, acanthosis nigricans, hypertrophic cardiomyopathy, and hyperinsulinemia
  • Cross-references include OMIM 269700, 608594, 612526, and 613327, used to label the four molecular subtype descriptions.

PubMed Records

  • PMID:11967537 Agarwal et al. 2002
  • Identifies AGPAT2 mutations in congenital generalized lipodystrophy linked to 9q34.
  • Supports autosomal recessive inheritance, marked adipose tissue paucity, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis, early diabetes, and impaired triacylglycerol synthesis/storage in adipocytes.
  • PMID:11479539 Magre et al. 2001
  • Identifies the chromosome 11q13 BSCL2/seipin disease gene in Berardinelli-Seip congenital lipodystrophy families.
  • Supports severe disruption of seipin and clinical features including acanthosis nigricans, hepatomegaly, diabetes, muscle hypertrophy, and hypertriglyceridemia.
  • PMID:12362029 Van Maldergem et al. 2002
  • Cohort genotype-phenotype analysis of 70 affected subjects.
  • Supports BSCL2-associated higher prevalence of intellectual impairment, molecular diagnosis, genetic counseling implications, hepatic dysfunction, hyperlipidemia, diabetes, hypertrophic cardiomyopathy, and subtype severity differences.
  • PMID:22269949 Chen et al. 2012
  • Bscl2 knockout mouse and cell differentiation study.
  • Supports severe white-adipose lipodystrophy, dyslipidemia, insulin resistance, hepatic steatosis, failure of terminal adipocyte differentiation, lipid-droplet loss, and activated lipolysis mechanisms.
  • PMID:25734254 Diker-Cohen et al. 2015
  • Prospective, single-arm, open-label metreleptin study in generalized and partial lipodystrophy.
  • Supports metreleptin use in generalized lipodystrophy and reductions in HbA1c and triglycerides.
  • PMID:26239609 Patni and Garg 2015
  • Full-text review of congenital generalized lipodystrophy pathophysiology and treatment.
  • Supports the four subtype genes AGPAT2, BSCL2, CAV1, and PTRF/CAVIN1; convergence on phospholipid/triglyceride synthesis, lipid droplets, and caveolae; ectopic triglyceride accumulation in liver and skeletal muscle; severe hypoleptinemia; dietary management; conventional diabetes and lipid therapy; and metreleptin replacement.

Curation Conclusions

The curated mechanism model treats Berardinelli-Seip congenital lipodystrophy as a genetically heterogeneous but convergent adipocyte lipid-storage disorder. AGPAT2 deficiency impairs phosphatidic acid production for triglyceride and glycerophospholipid synthesis. BSCL2/seipin deficiency disrupts lipid-droplet organization and terminal adipocyte differentiation. CAV1 and CAVIN1/PTRF defects impair caveola structure or biogenesis, reducing adipocyte lipid handling and expandability. These upstream defects cause generalized adipose tissue loss. The inability to store triglyceride in adipose tissue diverts lipid to liver and skeletal muscle, producing hepatic steatosis, hypertriglyceridemia, hepatomegaly, and severe insulin resistance. Near-total adipose loss also causes hypoleptinemia, worsening hyperphagia and metabolic derangement.

Management is metabolic and supportive: metreleptin replacement addresses leptin-deficiency-driven metabolic complications in generalized lipodystrophy; low-fat dietary management aims to reduce triglyceride burden; conventional diabetes and hyperlipidemia therapy treats downstream complications; and genetic counseling is warranted for autosomal recessive recurrence risk and subtype-specific prognosis.